Novavax said that its updated XBB-targeting Covid-19 vaccine showed neutralizing antibody response toward XBB subvariants EG.5.1 and XBB.1.16.6.
The exact specifics of the data, obtained from small animal and non-human primate studies, remain undisclosed. The biotech added that XBB sublineage variants make up the majority of…
Click here to view original post
